Exhibit 12.1
Sorrento Therapeutics, Inc.
Ratio of Earnings to Fixed Charges
(in thousands) | Nine Months Ended September 30, | Fiscal Year Ended December 31 | ||||||||||||||||||||||
| 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||||||||||||||||||
| Pretax Income (Loss) from Continuing Operations | $ | (61,962 | ) | $ | (64,833 | ) | $ | (13,760 | ) | $ | (36,359 | ) | $ | (21,911 | ) | $ | (4,845 | ) | ||||||
| Fixed Charges (per below) | ||||||||||||||||||||||||
| Interest Capitalized | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
| Earnings | $ | (61,962 | ) | $ | (64,833 | ) | $ | (13,760 | ) | $ | (36,359 | ) | $ | (21,911 | ) | $ | (4,845 | ) | ||||||
| Interest and Other Financial Charges | 4,028 | 1,615 | $ | 1,651 | $ | 1,628 | $ | 254 | $ | 0 | ||||||||||||||
Fixed Charges | $ | 4,028 | $ | 1,615 | $ | 1,651 | $ | 1,628 | $ | 254 | $ | 0 | ||||||||||||
| Ratio of Earnings to Fixed Charges | (15.4 | ) | (40.1 | ) | (8.3 | ) | (22.3 | ) | (86.3 | ) | n/a | |||||||||||||
